SELLAS Nears REGAL Final Analysis with 78 of 80 Events; Cash Runway Strong

What happened

SELLAS Life Sciences reported that 78 overall survival events have been recorded in its Phase 3 REGAL trial of galinpepimut-S in AML, just two short of the 80-event trigger for final analysis. Management remains blinded and expects the final analysis to follow after the 80th event, though the timeline for database lock and topline readout is not specified. The company ended Q1 with $107.1 million in cash, supplemented by an additional $7.5 million from warrant exercises in Q2, providing ample runway through the catalyst. Meanwhile, the Phase 2 SLS009 trial in first-line AML is actively dosing patients, adding a secondary catalyst. However, the $150 million at-the-market offering and large warrant overhang persist, diluting per-share value if the stock appreciates.

Implication

The 78-event update reduces the tail risk of a prolonged wait, but the final step to 80 events and subsequent analysis steps still introduce uncertainty. The company's cash runway is adequate through 2026, but the $150 million ATM overhang could cap upside if used aggressively. The bullish scenario of a mid-2026 topline readout is now more plausible, but the bear case of timeline slippage remains. Investors should focus on the announcement of the 80th event and management's guidance on database lock to gauge timing. Until then, the risk/reward is balanced given the binary nature and potential dilution.

Thesis delta

The thesis shifts from 'wait for the 80th event' to 'wait for clarity on the post-event timeline to topline data.' While the event trigger is now imminent, the stock may react to the 80th event announcement, but the real value inflection is the topline readout, which remains uncertain in timing. The probability of a near-term catalyst has increased, but the dilution overhang and binary outcome still warrant a cautious stance.